Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients

Genetic variations in CYP3A4, CYP3A5, and m-TOR could contribute to interpatient variability regarding m-TOR inhibitors pharmacokinetics or cellular effects. The purpose of this study was to evaluate the influence of selected candidate variations in these genes on everolimus pharmacokinetics, effica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The pharmacogenomics journal 2020-10, Vol.20 (5), p.647-654
Hauptverfasser:	Bonnet, Stéphanie, Falkowski, Sabrina, Deppenweiler, Marine, Monchaud, Caroline, Arnion, Hélène, Picard, Nicolas, Woillard, Jean-Baptiste
Format:	Artikel
Sprache:	eng
Schlagworte:	45/77 631/208/205 692/499 Biomedical and Life Sciences Biomedicine Blood cancer Breast Cancer Cancer patients Cytochrome P-450 Drug therapy Gene Expression Gene polymorphism Genetic aspects Genetic diversity Genetic polymorphisms Haplotypes Health aspects Human Genetics Inhibitor drugs Neuroendocrine tumors Oncology Pancreas Patient outcomes Patients Pharmacodynamics Pharmacokinetics Pharmacology, Experimental Pharmacotherapy Psychopharmacology Targeted cancer therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!